Antengene Corporation Limited will present new data from two clinical studies of selinexor at the 2024 American Society of Hematology (ASH) Annual Meeting, held December 7-10 in San Diego, CA. The presentations will highlight selinexor's potential in treating relapsed/refractory multiple myeloma (RRMM) and extranodal NK/T-cell lymphoma (R/R ENKTL).
Selinexor, Bortezomib, and Dexamethasone (SVd) in Relapsed/Refractory Multiple Myeloma
The primary analysis of the Phase III Bench study (Abstract #4748) will feature data on weekly selinexor, bortezomib, and dexamethasone (SVd) compared to twice-weekly bortezomib and dexamethasone (Vd) in Chinese patients with RRMM. This study, led by Dr. Jin Lu from Peking University People’s Hospital and Dr. Jian Hou from Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, investigates the efficacy and safety of the SVd regimen in a patient population with limited treatment options. Multiple myeloma remains a significant challenge, with relapse being common despite advancements in treatment. The study aims to provide a more effective and tolerable treatment option for these patients.
Selinexor with Tislelizumab in Relapsed/Refractory Extranodal NK/T-Cell Lymphoma
Preliminary results from Arm C of the Phase I/II TOUCH study (Abstract #4448) will showcase selinexor combined with tislelizumab in patients with R/R ENKTL. This multi-center, single-arm study, led by Dr. Rong Tao from Fudan University Shanghai Cancer Center and Dr. Huiqiang Huang from Sun Yat-Sen University Cancer Center, explores the potential of this combination therapy in a difficult-to-treat lymphoma subtype. Extranodal NK/T-cell lymphoma is an aggressive malignancy with poor prognosis, especially in relapsed or refractory cases. The study seeks to address the unmet need for effective therapies in this patient population.
About Selinexor
Selinexor (XPOVIO®) is an orally-available, selective inhibitor of nuclear export (SINE) compound. By blocking the nuclear export protein XPO1, selinexor promotes the accumulation of tumor suppressor proteins within the nucleus, reduces the levels of oncogenic proteins in the cytoplasm, and restores hormone sensitivity. This unique mechanism of action allows selinexor to exert antitumor effects through multiple pathways, making it a promising candidate for combination therapies across various cancer types. Antengene is currently conducting multiple clinical studies of selinexor in mainland China for relapsed/refractory hematologic malignancies and solid tumors.
